Federal grants to Marpam Pharma LLC
Marpam Pharma LLC in Saint Paul, Minnesota received $5.1 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Allergy and Infectious Diseases Research, with $5.1 million. In fiscal 2025 it was awarded $897,723.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$5.1 million
- Awards5
- Awarded in FY 2025$897,723
- Largest award$2.3 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $1.1 million |
| FY 2022 | 2 | $1.3 million |
| FY 2023 | 3 | $480,024 |
| FY 2024 | 2 | $1.3 million |
| FY 2025 | 1 | $897,723 |
Programs that fund Marpam Pharma LLC
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 5 | $5.1 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $5.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| A novel car-t cell therapy for the one-time treatment of chronic HIV infection in patients who are not art suppressed - abstract building on our successful primate model studies, we aim to develop a one-time treatment for durable remission of human immunodeficiency virus (HIV) in the absence of anti | Allergy and Infectious Diseases Research | July 5, 2022 | $2.3 million |
| Development of a treatment for the durable remission of HIV using autologous human car t cells that target b cell follicles - abstract marpam pharma is developing a one-time treatment for durable remission of human immunodeficiency virus (HIV) for patients treated with antiretroviral therapy (ART). | Allergy and Infectious Diseases Research | August 9, 2021 | $2.1 million |
| Development of a treatment for durable remission of HIV using transposon engineered car-t and nk cells - project summary marpam pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretr | Allergy and Infectious Diseases Research | December 7, 2022 | $306,500 |
| Proof of concept studies for in vivo produced car-t cells that target b cell follicles as a treatment for HIV - abstract marpam pharma is developing a chimeric antigen receptor (CAR)-t cell treatment that targets viral reservoirs for durable remission of HIV without the need for antiretroviral thera | Allergy and Infectious Diseases Research | March 14, 2024 | $302,248 |
| Development of a treatment for the durable remission of HIV using autologous human car t cells that target b cell follicles | Allergy and Infectious Diseases Research | February 18, 2021 | $52,000 |
Questions people ask
How much federal grant money does Marpam Pharma LLC get?
$5.1 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Marpam Pharma LLC the most?
The Department of Health and Human Services, with $5.1 million in 5 awards.
What is Marpam Pharma LLC's largest federal grant?
$2.3 million under Allergy and Infectious Diseases Research, with its first action in the period on July 5, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Saint Paul
- Minnesota Department of Human Services
- Minnesota Department of Transportation
- Department of Commerce Minnesota
- Minnesota Department of Health
- The State of Minnesota of Employment & Economic Development
- Minnesota Department of Public Safety
- Judiciary Courts of State of Minnesota
- Minnesota Public Facilities Authority
Largest federal grant recipients in Minnesota · Federal grants in Minnesota